RXL-3RT 30mg Peptide | Third-Party Tested | RemedyX Labs
Order RXL-3RT 30mg research peptide online from RemedyX Labs. Verified batch COAs confirm purity and identity. Secure checkout, competitive pricing, and fast shipping.
RXL-3RT is a synthetic research peptide supplied as a lyophilized powder. It is used in controlled laboratory studies of multi-receptor signaling and metabolic research models. Every batch is independently tested by a third-party laboratory to confirm identity and purity, with batch-specific Certificates of Analysis (COA) available for full transparency. For laboratory research use only. Not for human or animal use. Not intended for diagnostic, therapeutic, clinical, or commercial use.
- Price: 99.00 USD
- In stock
- Purity: 99%+
- CAS Number: 2381089-83-2
- Molecular Formula: C221H342N46O68
- Molecular Weight: 4731
- Specification: 30mg/vial
- Contents: Lyophilized Powder
- Appearance: White to Off-White
- Intended Use: Research Only
- SKU: RXL-SKU-0026
Cited Research
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
This phase 2 trial investigates the clinical impact of the triple-hormone-receptor agonist retatrutide on obesity.
PubMed, 2023
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes
Researchers studied the application of the triple agonist retatrutide in subjects diagnosed with type 2 diabetes.
PubMed
Structural Insights into the Triple Agonism at GLP-1R, GIPR and GCGR Manifested by Retatrutide
This study provides structural analysis of retatrutide's triple-agonist activity at the GLP-1, GIP, and glucagon receptors.
PubMed
The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying
This study explored the physiological impact of the triple agonist retatrutide on the rate of gastric emptying.
PubMed, 2023
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
A phase 2a randomized trial assessed the impact of the triple hormone receptor agonist retatrutide on metabolic dysfunction-associated steatotic liver disease.
PubMed, 2024
Inotropic effects of retatrutide in isolated human atrial preparations
Researchers analyzed the inotropic effects of retatrutide using isolated human atrial tissue preparations.
PubMed, 2026
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review
This comprehensive review examines the potential role of the triple hormone receptor agonist retatrutide in managing cardiovascular-kidney-metabolic syndrome.
PubMed, 2026
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
A systematic review and meta-analysis synthesized data from randomized controlled trials on the efficacy and safety of retatrutide for obesity treatment.
PubMed, 2025
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
This clinical trial substudy utilized DXA scanning to measure changes in body composition among patients with type 2 diabetes treated with retatrutide.
PubMed, 2025
Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge
The study investigated the impact of retatrutide on steatohepatitis in an accelerated mouse model featuring diet-induced disease and a fructose challenge.
PubMed, 2025
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist
Finds significant weight and metabolic improvements with a generally expected incretin-class adverse-event profile.
PubMed, 2025
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Reviews mechanism, dose-response findings and ongoing development.
PubMed, 2025
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers
Reports significant weight and metabolic improvements across available trials.
PubMed, 2024
Unleashing the power of retatrutide: a possible triumph in obesity pharmacotherapy
Critically discusses the early clinical program and feasibility questions.
PubMed, 2024
Retatrutide for the treatment of obesity, obstructive sleep apnea and osteoarthritis: TRIUMPH program
Describes the phase 3 TRIUMPH program rather than completed efficacy results.
PubMed, 2026
Efficacy and safety of retatrutide as monotherapy in adults with type 2 diabetes
Reports glycemic and body-weight improvements in a diabetes trial.
PubMed, 2026
Retatrutide for obesity: current evidence and future directions
Synthesizes available early-phase evidence and outstanding safety questions.
PubMed, 2025